Physician

Ralph Gousse, M. D.

According to 2025 Medicare claims, Ralph Gousse, M. D. (NPI: 1457316341) practices hematology/oncology in the Orlando-Kissimmee-Sanford, FL market, with the plurality of this provider's patient population coming from Lake, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32701-5621.

Gousse's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,263 traditional Medicare patients, billed 342,866 HCPCS/CPT codes, and received $4,948,577 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,824 prescription claims across 357 beneficiaries totaling $8,471,416 in drug costs, led by Revlimid (Lenalidomide). 2021 DME data shows 52 claims. Open Payments data shows 91 records totaling $1,970. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,931,524 to $8,471,416. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,408	356,589	$3,064,586
2016	1,477	488,790	$4,331,831
2017	1,491	486,649	$4,720,807
2018	1,610	626,954	$6,490,329
2019	1,531	579,909	$5,792,422
2020	1,380	481,640	$5,263,707
2021	1,307	425,281	$4,694,281
2022	1,086	380,516	$4,197,777
2023	1,103	348,837	$4,105,616
2024	1,263	342,866	$4,948,577

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	272	1,293	$1,931,524
2016	286	1,304	$2,831,693
2017	312	1,482	$3,363,657
2018	342	1,689	$4,616,862
2019	353	1,583	$5,056,009
2020	348	1,682	$5,580,367
2021	360	1,809	$5,467,129
2022	350	1,724	$6,130,181
2023	360	1,604	$5,608,827
2024	357	1,824	$8,471,416

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	225	$97,856
2016	33	268	$94,937
2017	N/R	70	$22,526
2018	N/R	N/R	N/R
2019	N/R	12	$2,330
2020	N/R	13	$1,849
2021	N/R	52	$3,217
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	340	781	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	778	1,389	$63
96372	Injection of drug or substance under skin or into muscle	374	1,571	$10
36415	Insertion of needle into vein for collection of blood sample	948	3,740	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	851	3,537	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	108	2,646	$1,740,646
Pomalyst	Pomalidomide	43	1,204	$826,462
Brukinsa	Zanubrutinib	44	1,320	$628,080
Imbruvica	Ibrutinib	32	896	$500,076
Cabometyx	Cabozantinib S-Malate	19	570	$468,796

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	91	$1,970	Gilead Sciences, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ralph Gousse, M. D.?

Tedicare shows public-source Medicare data for Ralph Gousse, M. D. (NPI 1457316341), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ralph Gousse, M. D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ralph Gousse, M. D.?

Ralph Gousse, M. D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Ralph Gousse, M. D. have Open Payments data?

Ralph Gousse, M. D. has 91 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.